BridgeBio Oncology Therapeutics Presents at Major Conference
BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT), a pioneering clinical-stage biopharmaceutical enterprise focused on overcoming RAS-pathway malignancies, has announced significant poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This prestigious event is scheduled for October, where renowned experts from around the world will gather in Boston to discuss the latest advancements in cancer treatment.
Insight into the Conference
The AACR-NCI-EORTC conference is a vital platform that brings together thought leaders and researchers in the field of molecular targets and cancer therapeutics. The event aims to foster collaboration, drive innovation, and share critical scientific findings that could impact cancer treatment. The conference emphasizes the importance of translating laboratory discoveries into clinical practices, ensuring that patients have access to cutting-edge therapies.
BBOT's Abstracts Overview
BBOT’s participation is underscored by two compelling poster presentations that reflect the company’s commitment to developing groundbreaking therapies that target cancers driven by the most prevalent oncogenes. The abstracts scheduled for presentation provide a glimpse into BBOT’s innovative approach to treating KRAS and PI3K? related cancers.
Poster Presentation Highlights
The first poster is titled BBO-11818, which represents a novel orally bioavailable and highly potent inhibitor designed to target both pan-KRAS(ON) and (OFF). This innovative therapy has shown robust anti-tumor activity in preclinical models featuring KRAS mutations. The presentation will be part of Poster Session A on October 23, with Dr. Carlos Stahlhut, Associate Director of BBOT, serving as the presenter.
Another noteworthy presentation will focus on BBO-10203, a first-in-class breakaway molecule that selectively disrupts the RAS:PI3K? interaction. This therapy has demonstrated the potential to inhibit tumor growth effectively, both alone and in combination with KRAS inhibitors, without causing hyperglycemia—a significant advancement in the field. Dr. Kerstin Sinkevicius, Vice President of Pharmacology at BBOT, will present this research during Poster Session C on October 25.
BBOT's Vision and Commitment
BridgeBio Oncology is dedicated to crafting a next-generation pipeline of small molecule therapeutics that focus on addressing cancers driven by RAS and PI3K? mutations. The company's mission revolves around developing innovative treatment options that aim to enhance patient outcomes, especially for those afflicted by these challenging cancers. By participating in conferences such as AACR-NCI-EORTC, BBOT reinforces its dedication to advancing oncological research and innovation.
Connect with BBOT
To learn more about BridgeBio Oncology Therapeutics, visit www.bbotx.com, where additional information about their latest research and innovations can be accessed. You can also engage with them on social media platforms like LinkedIn to stay updated on their endeavors in the oncology landscape.
BBOT Contacts
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
Frequently Asked Questions
What does BBOT specialize in?
BBOT specializes in developing innovative therapies for cancers driven by RAS and PI3K? mutations.
When is the AACR-NCI-EORTC conference?
The conference is scheduled for October 22-26 in Boston.
Who will present on the first day of the event?
Dr. Carlos Stahlhut will present the BBO-11818 abstract on October 23.
What is significant about BBO-10203?
BBO-10203 is a first-in-class molecule designed to inhibit tumor growth without causing hyperglycemia.
Where can I find more information about BBOT?
More information can be found on their official website at www.bbotx.com.
